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Tuberculosis (TB) continues to disproportion-
ately afflict persons incarcerated in correctional
facilities in the United States (U.S.).  A recent
study examining surveillance data for all per-
sons with TB disease reported in the U.S.
between 1993 and 2003 found that the rate of
TB disease among federal (29.4
cases/100,000) and state (24.2/100,000) prison
inmates was markedly higher than the rate
among non-inmates (6.7/100,000) (see
Literature Review).
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Over half (53.7%) of the
inmates with TB disease were housed in local
jails, and compared to non-inmates, they were
younger, more likely to be male, US-born and
from racial and ethnic minorities.  Not surpris-
ingly, inmates more often had a history of
excess alcohol use, illicit drug use and home-
lessness during the year prior to TB diagnosis.
Co-infection with human immunodeficiency
virus (HIV) was common among inmates with
TB disease.  Among males between the ages of
18 and 64, 25% of the incarcerated were known
to be HIV-infected compared to 18% for non-
inmates.  Further, despite a higher rate of
directly observed therapy among inmates than
non-inmates, treatment completion rates tend-
ed to be worse among inmates than non-
inmates, particularly among those who were
HIV-infected.  
As most prisoners with TB are eventually
released, failure to complete treatment in this
population poses a significant risk not only to
the individual health of the patient, but also to
the public health of the community.   While the
study did not examine the reasons for worse TB
treatment outcomes among inmates, several
factors may have been contributory.  The study
spanned 1993 to 2003, and during the early
part of this period, TB control efforts were
simultaneously recovering from the relative
neglect of the previous decade and coping with
the emerging HIV/AIDS epidemic.  Additionally,
the authors suggest that the poor inmate out-
comes observed may be the product of  frag-
mentation of care in correctional settings due to
inmate transfer between institutions and
release from incarceration, which challenge
coordinated care to ensure treatment comple-
tion.  Certainly, socioeconomic factors associat-
ed with incarceration may have posed a barrier
to healthcare as those who are incarcerated
may have less access to care and/or under-uti-
lize care.     
Local jails have been particularly implicated in
TB transmission, and TB control has been chal-
lenging in this setting.  A study of TB cases in
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Maricopa County, Arizona, published in
2005, demonstrated the challenges of TB
control in jails.
2
Of 300 TB cases reported in
the county from 1999 to 2000, 73 (24%)
occurred in persons who had a history of
incarceration in the county jail.  Similar to
national statistics, TB patients with a histo-
ry of incarceration had higher rates of
homelessness and substance abuse than
other TB patients.  The TB patients in the
study who had been in the county jail were
incarcerated a total of 370 times, but spent
a median of only two days in jail each time
they were incarcerated.  This short length
of stay and the requirement of at least 48
hours to place and read a tuberculin skin
test (TST) may explain why 83% of inmates
had no record of tuberculin skin testing in
jail.  Innovative strategies for screening
(e.g. Quantiferon-Gold®, see below) and
enhanced follow-up after incarceration are
needed to target this high-risk population. 
Occupational Hazard of TB Infection
among Healthcare Workers in Prisons
and Jails
TB is an occupational hazard for healthcare
professionals who work in correctional set-
tings.  Past studies have demonstrated a
relatively high incidence of latent TB infec-
tion (LTBI) in correctional healthcare work-
ers,
3
with infection rates estimated to be as
high as 6.6%.
4
However, a recent study of
correctional healthcare workers suggested
that a significant proportion of LTBI may be
acquired outside the workplace.5 The study
authors surveyed correctional healthcare
professionals in Rhode Island, Maryland
and Texas.  Tuberculin skin testing prac-
tices varied by site, and two-step testing
(i.e. repeat tuberculin skin testing one to
three weeks following an initial negative
TST result) was generally not used.  The
prevalence of LTBI was 18%, with an esti-
mated infection rate of 1.3%/year.  The risk
of TB infection correlated with birth in a
high-incidence country, but not with job
title, duration of employment or TB screen-
ing practices in the workplace.  
The results of this study reinforce the
importance of TB screening among correc-
tional healthcare staff at the time of hire
and the use of the two-step testing proce-
dure to distinguish prior TB infection from
infection acquired in the workplace
Persons with remote TB infection may have
a negative TST on initial testing, but place-
ment of the TST stimulates the immune
system, which may cause the next TST to
be positive in a previously infected person.
If the next TST is placed one to three
weeks later, it is unlikely that a new expo-
sure to TB has occurred; a positive TST
likely represents a boosting of the immune
response and not new infection.  If two-step
testing is not performed, a positive TST
during screening the following year will be
interpreted as recent TB infection when in
fact it may represent immune boosting.
Continued refinement of TB surveillance
strategies will be necessary to accurately
detect ongoing TB transmission in the high-
risk correctional environment. 
To assist in protecting healthcare workers,
in December 2005 Centers for Disease
Control and Prevention (CDC) released
"Guidelines for Preventing the
Transmission of Mycobacterium tuberculo-
sis in Health-Care Settings, 2005."
6
The
document divides healthcare facilities into
low risk, medium risk and potential ongoing
transmission settings, based on the num-
ber of patients with TB disease seen at the
facility.   The recommended frequency of
healthcare worker TST screening varies
depending on the facility risk level.
Correctional healthcare facilities are classi-
fied as medium risk unless ongoing TB
transmission is identified and all correction-
al healthcare facilities should have a written
TB infection control plan.  
In medium risk settings, all healthcare
workers should receive baseline TB
screening upon hire (either with two-step
tuberculin skin testing or a single interfer-
on-γ release assay, e.g. QuantiFERON®).
After baseline testing, healthcare workers
should receive TB screening annually,
including screening for symptoms and
either tuberculin skin testing or interferon-γ
release assay for persons with previously
negative tests.  Healthcare workers with a
positive baseline test, a newly positive test
or documentation of previous treatment for
latent or TB disease should receive one
chest radiograph to exclude TB disease.
Yearly chest radiographs are not needed
unless TB symptoms are present.  In the
setting of ongoing transmission within a
facility, TB testing may need to be per-
formed as frequently as every eight to 10
weeks until there is no further evidence of
TB transmission.  
Of course, any healthcare worker with LTBI
(positive TST or interferon-γ release assay,
no evidence of active TB disease) should
be offered treatment to reduce the risk of
future TB disease (See this month's Case
Study 1).  Tuberculin skin testing should
generally not be performed in individuals
with a history of a strong positive result in
the past.  Severe reactions can be trig-
gered with repeat skin testing in such per-
sons.  
TB in the HIV-Infected Inmate
HIV co-infection continues to be a signifi-
cant challenge in treatment of persons with
TB.  A recent study of 367 patients with
HIV/TB co-infection treated in six cities
across the U.S. highlighted the difficulties
encountered in treating patients with both
infections.
7
Patients had been diagnosed
with TB between 1986 and 2000, with 17%
diagnosed in 1997 or later - a period during
which potent antiretroviral therapies
became available.  Intolerance of TB drugs
was common; 16% of patients required a
change in TB treatment regimen due to
drug intolerance (see this month's Case
Study 2). Drug interactions were another
common problem; 73% were concurrently
prescribed rifamycins (rifampin, rifabutin)
and HIV medications known to interact with
rifamycins.  Treatment was also complicat-
ed by poor adherence and concurrent liver
disease.  Poor adherence to TB therapy
was noted in 38% of cases, and liver dis-
ease was present either prior to or during
TB treatment in 25% of patients with
HIV/TB co-infection.   Only 62% of patients
completed TB treatment and 17% of
patients with HIV/TB co-infection died with-
in 12 months of TB diagnosis.   
Fortunately, understanding of pharmacoki-
netic interactions among drugs used to
treat TB and HIV continues to improve.
(Updated guidelines for concurrent HIV/TB
treatment are available at www.hivatis.org.
This month's IDCR-o-GRAM lists major
interactions between TB and HIV thera-
pies.)  In general, the nucleoside reverse
transcriptase inhibitors (NRTIs) only have
minor interactions with TB drugs, and no
dosing adjustments of either TB or HIV
medications are necessary when using HIV
regimens containing only nucleoside
agents.  Serum concentrations of all the
available non-nucleoside (NNRTI) agents
(delaviridine, efavirenz and nevirapine) are
reduced by concurrent rifampin administra-
tion, and among these agents, only
efavirenz is currently recommended for use
in patients receiving rifampin.  
A major concern has been the dosing of
rifabutin with efavirenz, as both induce
cytochrome P450 enzymes.  A recent study
provided empiric support for the recom-
mendation to increase rifabutin dosing for
TB treatment in combination with efavirenz-
based regimens.  The Tuberculosis Trials
Consortium studied 15 patients who
received standard doses of isoniazid plus
rifabutin dosed 600 mg twice-weekly during
the continuation phase (the last four
months) of TB treatment.
8
These patients
also received standard-dose efavirenz (600
mg daily) plus two NRTIs for HIV treatment.
2
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Dear Corrections Colleagues,
A number of infectious diseases are concentrated among those incarcerated in jails and pris-
ons.  Of these, tuberculosis (TB) stands out, as it is a highly infectious airborne pathogen that
every once in a while is resistant to one or more standard anti-mycobacterials.  Procedures to
prevent the spread of TB, such as the screening of inmates and staff, fitting of protective masks
and maintenance of negative pressure rooms, occupy a significant amount time for many of us
- as does the management of those with latent and active TB infection. 
In this issue of IDCR, Duke University infectious diseases specialist Dr. Beth Gadkowski, along
with Dr. Jason Stout of the North Carolina Tuberculosis Control Program review major develop-
ments in the management of TB, highlighting those areas of particular relevance to health care
providers in correctional settings.  After reading this issue, individuals should be able to describe
techniques for TB screening and the management of TB in the HIV-infected inmate.  A table of
drug interactions between antiretrovirals and TB medications with recommended dose modifi-
cations accompanies the article and is worth keeping handy. 
This is the final issue that Courtney Colton will serve as Managing Editor before moving on to
become Development Director at a charitable organization.  Since October 2004 Courtney has
been responsible for getting IDCR to you and this she has done superbly.  All of us at IDCR
thank Courtney and wish her all the best.
As always, please feel free to send comments and suggestions to me at wohl@med.unc.edu.
Thanks,
David Alain Wohl, MD 
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The increased rifabutin dose was adequate
to compensate for efavirenz-induced
increases in drug metabolism; the therapy
was generally well tolerated and had potent
antiretroviral activity.  
Concurrent use of protease inhibitors with
rifampin is no longer recommended.
Although pharmacokinetic data suggested
that saquinavir/ritonavir would be effective
in combination with rifampin. In a recent
report, the combination of saquinavir/riton-
avir and rifampin was associated with 11
cases of significant transaminase elevation
among 28 healthy volunteers receiving this
combination, including one case that
required hospitalization.
9
The saquinavir/
ritonavir combination is, therefore, no
longer recommended for use with rifampin.
Rifabutin is the preferred rifamycin for
patients taking protease inhibitors, and the
dosages of rifabutin, the protease inhibitor,
or both must be adjusted to compensate for
the two-way interaction. (See this month's
IDCR-o-GRAM.)
Treatment of patients with HIV/TB co-infec-
tion with potent antiretroviral therapies has
led to increasing recognition of another
complication: immune reconstitution inflam-
matory syndrome (IRIS).  IRIS, defined as
clinical deterioration associated with
restoration of pathogen-specific immune
responses, has been associated with a
variety of pathogens including
cytomegalovirus, hepatitis B and C,
Pneumocystis jiroveci (formerly
Pneumocystis carinii), Cryptococcus neo-
formans and many others.  IRIS occurs in
19% to 36% of patients with HIV/TB co-
infection who receive both antituberculous
and antiretroviral therapy.
10,11
A recent
review of IRIS associated with mycobacter-
ial infections identified 86 published cases
of HIV/TB-associated IRIS.
12
IRIS occurred
in patients with low nadir CD4 counts
(median 51 cells/mm
3
) and was associated
with treatment-related significant increases
in CD4 counts and decreases in plasma
HIV RNA.  However, HIV/TB-associated
IRIS has been reported in patients with
baseline CD4 counts as high as 435. 
Extrapulmonary TB and starting antiretrovi-
ral therapy prior to completion of two
months of TB treatment have also been
associated with increased risk for IRIS.  In
contrast to IRIS associated with pathogens
such as M. avium, most persons with
HIV/TB-associated IRIS were receiving
antituberculous therapy at the time of IRIS
onset.  Patients typically presented with
fever, lymphadenopathy and worsening
respiratory symptoms between two to 10
weeks after starting antiretroviral therapy.
Lymphadenopathy, which could be periph-
eral (cervical, supraclavicular, inguinal, axil-
lary) or intrathoracic, was present in 71% of
cases.  Worsening pulmonary disease,
sometimes leading to respiratory failure,
occurred in 28% of cases.  Antiretroviral
therapy was interrupted because of IRIS in
15% of cases, and 7% required surgery to
treat IRIS-induced symptoms.  Although
some manifestations were life-threatening,
no deaths due to IRIS were reported.
Optimal treatment of IRIS is unclear, but
26% of patients received corticosteroids in
an attempt to diminish the exuberant
immune response.  Recognition of IRIS and
perhaps delaying antiretroviral therapy in
patients with HIV/TB co-infection who do
not have an urgent indication for antiretro-
viral treatment may reduce morbidity from
this condition.
Fluoroquinolones for TB Treatment 
Current guidelines recommend the use of
isoniazid, rifampin, ethambutol and pyrazi-
namide as first-line drugs for TB treat-
ment.
13
While the rate of multi-drug resis-
tant tuberculosis (MDR-TB), defined as
resistance to at least isoniazid and
rifampin, is low in the U.S., many patients
have difficulty tolerating one or more of the
first-line antituberculous agents.
14
However,
many of the available second-line agents
are poorly tolerated and less effective than
the first-line drugs.  The fluoroquinolones,
therefore, are increasingly promising
agents for TB treatment.  In fact, one of the
most important predictors of successful
treatment of MDR-TB is whether the TB
isolate demonstrates in vitro susceptibility
to a fluoroquinolone.
15
A recent systematic review examined 10
randomized trials that either substituted or
added fluoroquinolones to the treatment
regimen for pulmonary TB.
16
Older
quinolones, like ciprofloxacin and ofloxacin,
were associated with a higher incidence of
relapse and a longer time to sputum culture
conversion when substituted for one or
more first-line drugs (ofloxacin instead of
rifampin in one study, ciprofloxacin instead
of pyrazinamide plus ethambutol in anoth-
er) in patients with TB disease sensitive to
all of the first-line drugs. No difference in
any significant outcome was found compar-
ing a standard four drug regimen to four
drugs plus a newer fluoroquinolone, lev-
ofloxacin, for the first two months of treat-
ment in a patient population suspected to
have high rates of drug-resistant TB. Other
trials in drug-resistant TB compared fluoro-
quinolones (levofloxacin vs. ofloxacin and
sparfloxacin vs. ofloxacin) that were either
substituted or added to drug regimens.  In
these studies, the fluoroquinolone used did
not make a significant difference with
regard to cure rate or treatment failure.
Importantly, regimens including fluoro-
quinolones were not associated with an
increase in adverse events over standard
regimens.
In contrast, more impressive results were
reported from a recent study that substitut-
ed moxifloxacin for ethambutol during the
first eight weeks of pulmonary TB treatment
in sputum smear-positive patients.
17
A pre-
liminary analysis of 301 patients enrolled in
4
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February 2006 Case Series
L. Beth Gadkowski*, MD, MS
Jason E. Stout**, MD, MHS
Case Study 1.  Treatment of latent TB
infection.
A 32 year-old nurse at your correctional
facility presents for yearly TB screening.
He has no symptoms, no reported contact
with any inmates with TB, but his TST mea-
sures 11 mm.  A review of the record
reveals that his TST last year measured
0mm.  Chest radiograph reveals no signifi-
cant abnormalities.  What should be done
for this nurse?
Discussion:
The initial step after diagnosis of latent TB
is education.  The nurse should be informed
that persons with a normal immune system
have approximately a 5% risk to develop
active TB within the first two years after
infection (conversion of a negative TB skin
test to positive), and another 5% risk during
the rest of their lives.
19 
All individuals with a
positive skin test should be assessed for
medical conditions that would increase the
risk of progression to active TB.  HIV is the
single most important risk factor for pro-
gression to active disease; while ~10% of
HIV-negative, otherwise immunocompetent
persons will progress from TB infection to
TB disease in a lifetime, ~10% of persons
with HIV infection will progress YEARLY
without treatment!
20
All persons with latent
Continued on page 5
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TB infection should be offered HIV counsel-
ing and testing.
Treatment for latent TB infection usually
consists of nine months of isoniazid.
Isoniazid may be self-administered daily (5
mg/kg, maximum 300 mg), or may be
administered directly observed twice-week-
ly (15 mg/kg, maximum 900 mg).  Isoniazid
can be hepatotoxic, causing clinically signif-
icant hepatitis in 0.1-1% of patients who
take it for latent TB infection.
21, 22  
Persons
should be screened for symptoms of hepati-
tis every month while taking isoniazid, and
only a 1-month supply of the drug should be
dispensed at a time.  Persons at risk for
hepatotoxicity (e.g. HIV, viral hepatitis, alco-
hol use) should have transaminases drawn
prior to starting isoniazid and monthly there-
after until completion of therapy (see Case
Study 2).  
Those who are allergic or intolerant of isoni-
azid may be offered rifampin 10 mg/kg daily
(maximum 600 mg) for four months.  This
regimen is much more expensive than iso-
niazid, and rifampin interacts with many
other medications, particularly antiretrovi-
rals.  A two-month regimen of rifampin plus
pyrazinamide was formerly recommended,
but cases of severe hepatotoxicity and
death were associated with this regimen.
23
This regimen is considerably more toxic
than nine months of isoniazid and is now
generally not recommended for use.
24
Adherence to the nine-month regimen is
generally not very good.  A large study of a
shorter, once weekly combination of isoni-
azid and rifapentine is ongoing, and hope-
fully will provide an alternative to the current
nine-month regimen. 
In this case, the nurse was tested for HIV
infection and was seronegative.  He started
on daily isoniazid which he took for nine
months with only mild elevation in ALT and
AST.  
Case Study 2.  Intolerance of TB medica-
tions.
A 25 year-old, HIV-negative woman was
placed on 4-drug therapy (isoniazid,
rifampin, pyrazinamide, and ethambutol) for
culture-confirmed, extensive pulmonary
tuberculosis.  Three weeks after initiation of
therapy, she presented to sick call com-
plaining of a diffuse rash, fever, and fatigue.
Laboratory studies were significant for
aspartate aminotransferase (AST) of 423
(normal 0-40), alanine aminotransferase
(ALT) 652 (normal 0-40), alkaline phos-
phatase 135 (normal 0-150), and total biliru-
bin 2.2 (normal 0-1.3).  She was on no other
medications and denied use of over-the-
counter medications available at the facility
canteen, herbal remedies, alcohol, or illicit
drugs.  How should she be managed at this
point?
Discussion
Intolerance of drugs used to treat TB is a
common problem.  In addition to frequent
gastrointestinal symptoms, three of the four
first-line TB drugs (isoniazid, rifampin, and
pyrazinamide) are potentially hepatotoxic.
Hepatotoxicity associated with TB drugs is
idiosyncratic, often not associated with drug
dosage, and may have severe conse-
quences as illustrated in this case.
The general principles of dealing with hepa-
totoxicity from TB medications are listed
below:
z Mild increases in transaminases are
common and often of no clinical signifi-
cance.  TB therapy should be stopped in the
following cases:
 ALT>3x the upper limit of normal and
patient has symptoms of hepatitis OR
 ALT>5x the upper limit of normal and
patient is asymptomatic
z Elevated bilirubin in the setting of ele-
vated transaminases is a marker of more
severe hepatotoxicity and should prompt
immediate discontinuation of TB drugs and
close monitoring.
z If TB disease is mild, therapy may be
held until ALT<2x the upper limit of normal.
For patients with extensive or severe TB,
switch to treatment with a non-hepatotoxic
regimen (e.g. streptomycin + ethambutol +
moxifloxacin) while ALT improves
z Once symptoms resolve and ALT<2x
the upper limit of normal, sequentially rein-
troduce TB drugs with close clinical and lab-
oratory monitoring.  One protocol adds back
drugs 1 week apart, in the order ethambu-
tol, rifampin, isoniazid, and pyrazinamide
(order of lesser to greater potential for
hepatotoxicity).  In the case of severe hepa-
totoxicity, pyrazinamide may be omitted and
the regimen extended to at least 9 months if
isoniazid and rifampin are tolerated.
z Consult a TB expert if the patient can-
not be treated with standard first-line thera-
py.  Clinicians should not "make up" treat-
ment regimens for drug intolerant patients. 
z It is impossible to reliably predict which
drug caused the hepatotoxicity; using a
standard reintroduction protocol is essen-
tial.
z Monitoring for side effects of TB drugs
should be performed no less often than
monthly for patients being treated for either
latent or active TB.  Laboratory testing to
screen for hepatotoxicity should be per-
formed monthly only in patients at risk of
hepatotoxicity (concurrent hepatotoxic
drugs, chronic hepatitis, alcohol use, preg-
nancy, HIV).
z For patients with baseline elevated
transaminases or cirrhosis, careful monitor-
ing and expert consultation are essential.  In
the case of LTBI, the risks and benefits of
LTBI treatment should be carefully consid-
ered prior to initiating treatment.  Patients
with TB disease may require alteration of
the treatment regimen in concert with a TB
expert.
In the above case, isoniazid, rifampin, and
pyrazinamide were discontinued, and she
was treated with daily ethambutol, moxi-
floxacin, and intramuscular streptomycin.
Once the rash resolved and transaminases
improved, drugs were sequentially reintro-
duced a week apart.  The rash returned with
addition of isoniazid, and the patient was
successfully treated with six months of daily
rifampin, pyrazinamide, and ethambutol.
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this study prior to January 2005 demon-
strated that patients receiving moxifloxacin
converted their sputum cultures to negative
earlier than patients receiving ethambutol
(median 43 days for moxifloxacin vs. 56
days for ethambutol, p=0.01).  Moxifloxacin
was generally well-tolerated: fever, nausea
and dizziness were commonly reported, but
seldom resulted in treatment discontinua-
tion.  These results suggest that moxi-
floxacin is a useful second-line agent for TB
treatment, and studies are underway to
examine its utility as a first-line agent.  
Alternative TB Test 
The Mantoux TST in which 0.1 ml of tuber-
culin purified protein derivative is injected
into the inner surface of the forearm, is the
accepted method of evaluating for TB or
LTBI.  However, this test may be falsely
reactive in individuals who have received
the Bacille Calmette-Guèrin (BCG) vaccine.
The usefulness of TST is also limited by the
inherent variability in its administration and
interpretation.  QuantiFERON-TB Gold®
(QFT-G) was approved by the Food and
Drug Administration (FDA) in December
2004 as a diagnostic test for active TB and
LTBI.  The test measures the release of
interferon-gamma (IFN-gamma) when
whole blood is incubated with peptides
found in M. tuberculosis.  These peptides,
early secretory antigenic target-6 (ESAT-6)
and culture filtrate protein-10 (CFP-10), are
secreted from M. tuberculosis and patho-
genic M. bovis strains, but are not found in
BCG or nontuberculous mycobacteria
except M. kansasii, M. szulgai and M. mar-
inum.  As a result, QFT-G results are not
affected by previous BCG vaccination or
environmental exposure to nontuberculous
mycobacteria.  This test takes the place of
the first-generation QuantiFERON® test,
which is no longer being marketed.
The QFT-G test has the same logistical
issues as the first generation test.  Blood
drawn for the test needs to be incubated
less than 12 hours after being collected and
lab personnel require special training to
perform the assay. However, QFT-G results
are available in less than 24 hours and
unlike the TST, only one clinic visit is
required.  This makes QFT-G an attractive
testing option in clinical settings such as
homeless shelters and jails where follow-up
can be challenging.  QFT-G is also poten-
tially a cost-effective alternative to TST test-
ing in institutions like correctional facilities
and health care settings where false posi-
tive tests can prompt additional costly test-
ing.
The CDC released guidelines for use of
QFT-G in December 2005 (see
Resources).
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According to these guide-
lines, QFT-G may be used in all circum-
stances in which the TST is currently used,
including contact investigations, targeted
TST of high-risk groups such as immi-
grants, surveillance screening (such as in
healthcare workers or correctional facili-
ties), or as an aid to diagnosis of TB dis-
ease.  However, there is a paucity of data to
support the use of the test among immuno-
compromised persons (e.g. HIV-infected,
those on chronic corticosteroids, recipients
of tumor necrosis factor-alpha inhibitors,
etc.) or in children.  Furthermore, while the
QFT-G is likely more specific than the TST
for LTBI, it may be less sensitive than the
TST for detection of LTBI.  Use of QFT-G
instead of the TST in the correctional set-
ting, particularly in the setting of a signifi-
cant foreign-born incarcerated population,
seems attractive, but careful attention
should be paid to quality assurance and
impact on correctional system healthcare
costs. 
Conclusions
Despite continued decline in TB in the U.S.
as a whole, TB will continue to be a signifi-
cant problem within the correctional sys-
tem.  Available data indicate that greater
attention to the development and imple-
mentation of systems is urgently needed to
ensure prisoners and former inmates com-
plete TB treatment. Further, continued vigi-
lance and adherence to good infection con-
trol policies in prisons and jails will be vital
to protecting correctional healthcare work-
ers as well as others in the correctional set-
ting.  New diagnostic tools, including blood
tests for TB infection, are becoming avail-
able to improve TB diagnosis, but much
work remains to be done.  Shorter and bet-
ter tolerated regimens are needed for treat-
ment of both latent and active TB.
Treatment of persons co-infected with
HIV/TB continues to be challenging
because of high pill burden, drug interac-
tions and tolerability, but as HIV treatment
is simplified, some of these challenges may
be overcome.  IRIS is another important
challenge for HIV/TB co-infected patients,
and trials of different treatment strategies to
optimize IRIS management, including the
sequencing of TB and HIV therapy, are
underway.  The key to TB control is to
improve diagnosis and treatment in coun-
tries where TB is highly endemic; only by
controlling TB in the rest of the world is
there any hope of eliminating TB in the US.
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TUBERCULOSIS IN CORRECTIONS
(continued from page 4)
^In some correctional facilities two-step testing
for initial testing may provide a more reliable
baseline.
Note: Treatment of latent TB infection is only
indicated when the PPD is positive. The criteria
for a positive PPD are different depending on
HIV status but suspicion of contact (e.g. with
active, contagious TB case) or PPD > 5 mm are
the criteria for latent TB infection treatment of
HIV seropositives and PPD > 10 mm is criteria
for such treatment of non-immunocompromised
inmates.
Adapted from:  CDC.  Prevention and control of
tuberculosis in correctional facilities recommen-
dations of the advisory council for the elimina-
tion of tuberculosis.  MMWR.  1996; 45(RR-
8):1-27.
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Protocol for Screening Inmates for TB in Long-Term Correctional Facilities
IDCR-O-GRAM
Entry into facility
Screen inmate for symptoms of TB
Inmate does not have symptoms Inmate has symptoms
Obtain inmate's medical history.
Does inmate have a documented
history of a positive skin test result?
Isolate inmate and evaluate 
for possible TB disease.
YesNo
Administer and interpret result of
tuberculin skin test^
Did inmate complete treatment?
No; If inmate has not completed treatment,
obtain chest radiograph and evaluate for
therapy, especially if inmate is HIV-infected
Skin test is negative Skin test is positive
Determine whether inmate is
infected with HIV or is at risk 
for HIV but has unknown 
HIV status
Yes
Obtain chest radiograph
and evaluate for therapy
YesNo
Repeat skin test annually 
while incarcerated
Obtain chest radiograph and
evaluate for possible TB disease
Rifamycin Dosing in TB/HIV Co-infection Non-Nucleoside Reverse
Transcriptase Inhibitors
TB101: RIFAMYCIN DOSING IN TB/HIV CO-INFECTION
Consider increasing EFV to 800 mg QHS
No change necessary for Rifampin
Levels: EFV decreased by 25%
Efavirenz 
(EFV)
Contraindicated
Levels: DLV decreased by 95%
Delavirdine 
(DLV)
Not recommended
Levels: NVP decreased by 37-58%
Note: If alternative therapy not available, administer
standard doses of NVP and Rifampin and monitor
antiviral response and liver function tests closely as
combination may increase risk of hepatotoxicity
Increase Rifabutin to 450 mg daily
No dosing change necessary for EFV
Levels:
Rifabutin decreased by 35%
Contraindicated 
Levels :
DLV decreased by 80%
No dosing change necessary for Rifabutin or NVP
Levels: 
NVP decreased by 16%
Nevirapine 
(NVP)
Todd Correll*. PharmD, BCPS Nichole Kiziah**, PharmD
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Rifampin
Rifabutin
If NOT RTV
boosted:
Decrease
Rifabutin to 150
mg daily or 300
mg 3x/week; 
Increase IDV to
1000 mg every
8 hours
Levels:
Rifabutin
increased by 2-
fold
IDV decrease by
32%
If RTV boosted:
Decrease
Rifabutin 150
mg QOD or 150
mg 3x/week; No
IDV dose adjust-
ments are nec-
essary
Levels:
No Data
Decrease
rifabutin to 150
mg QOD or
dose 3x/week. 
Levels:
Rifabutin con-
centrations
increase 4-fold.  
If NOT boosted:
Contraindicated
If RTV boosted:
Decrease
Rifabutin 150
mg QOD or 150
mg 3x/week.
No SQV dose
adjustments are
necessary
Levels:
No Data
With NFV 1250
mg Q12H
decrease
Rifabutin to 150
mg QD or 300
mg 3x/week. 
No NFV dose
adjustments are
necessary
Levels:
No Data
If RTV NOT
concomitantly
administered:
Decrease
Rifabutin to 150
mg QD or 300
mg 3x/week. 
No f-APV dose
adjustments are
necessary
Levels:
Rifabutin
increased 1.9-
fold  
If RTV boosted:
Decrease
Rifabutin to 150
mg QOD or
3x/week.  
Levels: Rifabutin
increased
Decrease
Rifabutin dose
to 150 mg QOD
or 3x/week
No ATV dose
adjustments are
necessary
Levels: Rifabutin
increased 2.5-
fold
Decrease
Rifabutin dose
to 150 mg QOD
or 3x/week. 
No dose adjust-
ments are nec-
essary for LPV/r
Levels: Rifabutin
increased 3-fold. 
Decrease
Rifabutin to 150
mg QOD or
3x/week.  
Levels: Rifabutin
increased 2.9-
fold.  
Indinavir
(IDV)
Ritonavir
Full dose
(RTV)
Saquinavir
(SQV)
Nelfinavir
(NFV)
Fosamprenavir
(f-APV)
Atazanavir
(ATV)
Lopinavir*
(LPV)
Tipranavir*
(TPV)
Rifabutin
Contraindicated
Levels:
IDV (unboosted)
decreased 89%
IDV (boosted)
decreased 87%
Alternate antimi-
crobial should
be considered.  
Levels:
RTV decreased
by 35%.
.  
Contraindicated
Levels:
SQV levels
decreased by
84%.
Note: Severe
hepatotoxicity
observed with
Saquinavir 1000
mg/RTV 100 mg
Q12 hours +
Rifampin 600
mg daily
Contraindicated
Levels: 
NFV decreased
by 82%
Contraindicated
Levels: 
APV decreased
by 82%; 
Contraindicated
Levels:
No data
Contraindicated
Levels: 
LPV decreased
by75%
Limited clinical
experience sug-
gests LPV/r 3
SGC + RTV 300
mg BID may
overcome inter-
action.
Hepatotoxicity
may be associ-
ated with
increase RTV
dose.  Rifabutin
is recommended
instead of
Rifampin
No data
Should NOT be
co-administered
Rifampin
* Assumes ATV, LPV and TPV boosted with RTV
Notes:
NRTIs not expected to have clinically significant interactions with rifamycins.  For patients with CD4 cell counts <100 cells/mm3, daily or three times
weekly TB regimens are preferred.  If patients are not receiving NNRTI- or PI-based antiretroviral therapy, Rifampin can be used in place of Rifabutin.
If a three times weekly TB regimen is preferred, Rifabutin does not require dose alteration when concomitantly administered with a RTV boosted PI-
based antiretroviral regimen (i.e. if on ATZ/RTV the Rifabutin dose would be 150 mg every other day or three times per week). Please see recommen-
dation in above table for Rifabutin dosing recommendations when co-administered with a PI.  
If an Efavirenz-based regimen is used, Rifabutin 600 mg three times weekly is recommended.  
INH, PZA and EMB require escalation in doses if a three times weekly regimen is preferred.
References:
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.  Last accessed January 23, 2006 from
http://aidsinfo.nih.gov/guidelines/adult/AA_100605.pdf
TB/HIV Drug Interactions.  Last accessed January 23, 2006 from http://www.cdc.gov/nchstp/tb/TB_HIV_Drugs/Table1.htm
TB/HIV Drug Interactions. Last accessed January 23, 2006 from http://www.cdc.gov/nchstp/tb/TB_HIV_Drugs/Table2.htm
TB/HIV Drug Interactions. Last accessed January 23, 2006 from http://www.hiv-druginteractions.org/frames.asp?drug/drg_main.asp
8February 2006          Vol. 9, Issue 2 visit IDCR online at www.IDCRonline.org
Rifamycin Dosing in TB/HIV Co-infection Protease Inhibitors
TB101: RIFAMYCIN DOSING IN TB/HIV CO-INFECTION (CONT.)
Politics on Paper - Global
Tragedies/Personal Perils.
Featuring the work of Eric
Avery MD, John Risseeuw
and Robbin Ami Silverberg. 
January 13 - March 11, 2006
Columbia College Chicago
Center for Book & Paper Arts
1104 S. Wabash Ave
Chicago, IL 60605
Phone: 312.344.6684
13th Annual Conference on
Retroviruses and
Opportunistic Infections
February 5-9, 2006
Denver, Colorado
Visit:www.retroconference.org
13th Annual Ryan White
National Youth Conference
on HIV/AIDS
February 18-20, 2006
Philadelphia, Pennsylvania
Visit: www.napwa.org/rwnyc/
National Conference on
African-Americans and
AIDS
February 27-28, 2006
Philadelphia, PA
Visit: www.minority-health-
care.com/
NIMH/IAPAC Conference on
HIV Treatment Adherence
March 8-10, 2006
Jersey City, New Jersey
Visit: www.hivadherencecon-
ference.com
World TB Day
March 24, 2006
Visit: www.stoptb.org
Updates in Correctional
Health Care
April 8-11, 2006
Las Vegas, Nevada
Visit: www.ncchc.org
Satellite Videoconference
"Hepatitis B & C with HIV
Co-infection"
April 19, 2006
12:30-2:30 EST
CME-accredited webstream
of last conference available
on-line
Visit: www.amc.edu/patirnt/hiv
/hivconf/index.htm
ACHSA 2006
Multidisciplinary Training
Conference
May 11-13, 2006
Durham, North Carolina 
Visit: www.achsa.org
SAVE THE
DATES
9
TB Rates Higher in Prison Systems than
General Population
A recent study analyzed data reported to the nation-
al tuberculosis (TB) surveillance system from 1993
through 2003 and sought to describe disparities
and trends in TB risk factors and treatment out-
comes between correctional inmate and non-
inmate populations.  Of the 210,978 total reported
United States TB cases, 3.8% were from correc-
tional systems.  Federal and state prison case rates
were 29.4 and 24.2 cases per 100,000 inmates,
respectively, which was considerably higher than
those in the non-inmate population (6.7 cases per
100,000 persons.)  Inmates with TB were more like-
ly to have at least one TB risk factor (excess alco-
hol use, injection drug use, non-injection drug use,
homelessness and HIV) compared with non-
inmates (60.1% vs. 42.0%) and to receive directly
observed therapy (DOT) (65.0% vs. 41.0%).
However, inmates were less likely to complete
treatment within 12 months compared with non-
inmates (76.8% vs. 89.4% in 2001).  Rates of com-
pletion of therapy within 12 months were lower in
persons with TB risk factors and lowest for those
who had HIV infection at the time of TB diagnosis,
in both inmates and non-inmates, but lower among
inmates.  The authors concluded that TB case rates
in prison systems remain higher than in the gener-
al population and that inmates with TB are less like-
ly than non-inmates to complete treatment.  
MacNeil JR, Lobato MN, Moore M.  An unanswered health dis-
parity: tuberculosis among correctional inmates, 1993 through
2003.  Am J Pub Health.  2005; 95(10):1800-5.
San Francisco Jail Inmates 59x More Likely to
Develop Active TB
In a recent study, White, et al, measured rates of
development of active TB and completion of TB
therapy over five years in a cohort of inmates.  The
participants completed a randomized trial in 1998-
1999 comparing education/incentive versus usual
care to improve therapy completion after release
from the San Francisco County Jail (SFCJ).
Records from the SFCJ, the County TB Clinic and
the California TB Registry were used to measure
therapy completion and development of active TB.
Of a total of 557 inmates, 31.6% completed thera-
py, of whom 59.7% did so in jail, during the term of
the randomized trial or in subsequent incarcera-
tions.  Subjects who reported their country of birth
as Mexico were least likely to finish therapy as com-
pared to those from Central or South America,
South-east Asia or the United States.  Previous
therapy for TB and greater education were both
associated with TB therapy completion.  Three sub-
jects developed active TB during the five years of
follow-up, resulting in an annual rate of 108 per
100,000 inmates.  The standardized mortality ratio
calculated against the California case rate for 2003
(9.1 per 100,000) indicates that this sample was 59
times as likely as those in the general California
population to develop active TB.  Study authors
concluded that the high rate of TB seen in this jail
cohort emphasizes the importance of screening for
active TB, as well as improving efforts to ensure
treatment completion.
White M, Tulsky J, Menendez E, et al.  Incidence of TB in
inmates with latent TB infection: 5-year follow-up.  Am J Prev
Med.  2005; 29(4):295-301.
Avoid Use of Rifampin with Atazanavir/Ritonavir
According to recent reports, the combination of
Rifampin with Atazanavir (ATV) is no longer recom-
mended. Atazanavir is metabolized largely via
cytochrome P450 (CYP) 3A4 while Rifampin is
known to be a strong inducer of CYP3A4.
Therefore, unboosted ATV should not be prescribed
with rifampin.  Mallolas, et al hypothesizing that
boosting ATV with low-dose ritonavir (a CYP3A4
inhibitor) would negate the effect of rifampin on ATV
levels studied HIV-infected adults with a viral load
<200 copies/mL while receiving a triple nucleoside
regimen as well as 300 mg of rifampin daily as part
of a TB regimen.  ATV at a dose of (300 mg)/riton-
avir (100 mg) per day was added and a complete
pharmacokinetic study of ATV was performed three
weeks later.  In all of the first three of a total of eight
planned patients who enrolled in the study, the plas-
ma ATV Cmin, Cmax and AUC were undetectable.
Study authors concluded that even in the presence
of a low dose of ritonavir, there are clinically signifi-
cant interactions between ATV and rifampin leading
to a near absence of detectable ATV in the plasma.
Rifampin should not be administered together with
ATV even when the latter is ritonavir-boosted.
Mallolas J, Nomdedeu M, Soriano A, et al.  Pharmacokinetic
interaction between rifampin and the combination of atazanavir
and low dose ritonavir in HIV-infected patients.  Poster 123.  45th
Interscience Conference on Antimicrobial Agents and
Chemotherapy.  Washington, DC.  December 17, 2005.
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Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through February 28, 2006. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  According to national data the prevalence of TB disease (i.e.
active TB) among inmates is:
A. Half the rate of the non-incarcerated
B. The same as the rate of the non-incarcerated
C. 2 times the rate of the non-incarcerated
D. Over 3 times the rate of the non-incarcerated
2.  Each of the following statements regarding drug-drug interac-
tions between antiretrovirals and TB medications are true
EXCEPT:
A. Nucleoside reverse transcriptase inhibitors (NRTIs) have
only minor interactions with TB medications
B. Serum concentrations of all non-nucleoside reverse
transcriptase inhibitors (NNRTIs) are reduced by
rifampin
C. When administered with efavirenz the dose of rifabutin
must be lowered
D. Rifampin should generally not be co-administered with
protease inhibitors
E. None of the above
3. The following statements regarding the two-step tuberculin
skin testing are TRUE:
A. This procedure helps identify prior remote TB infection 
B. Should be considered for correctional healthcare work-
ers at the time of hire
C. Is well suited for use among inmates of jails and those 
frequenting homeless shelters
D. A and B
E. A and C
4.  Patients who develop an increase in ALT during treatment of 
TB disease should: 
A. Stop TB therapy if the ALT>3x the upper limit of normal 
and patient has symptoms of hepatitis 
B. Stop TB therapy if the ALT>5x the upper limit of normal 
and patient is asymptomatic
C. Restart TB therapy, if therapy is stopped, once symp-
toms resolve and ALT<2x the upper limit of normal with 
sequential reintroduction of TB drugs and close clinical 
and laboratory monitoring.
D. All of the above
5.  All inmates with diagnosed with HIV infection should be pre-
scribed treatment for latent TB regardless of tuberculin skin test-
ing result (TRUE or False)?
A. True
B. False
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